Pepgen Inc (PEPG)

$1.73 -0.01 (-0.57%)
Market Cap 119.57M
Revenue (ttm) 0.00
Net Income (ttm) -89.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,716,700
Avg Vol 1,342,894
Day's Range N/A - N/A
Shares Out 69.12M
Stochastic %K 10%
Beta 2.34
Analysts Strong Sell
Price Target $10.29

Company Profile

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study....

Industry: Biotechnology
Sector: Healthcare
Phone: 781 797 0979
Address:
321 Harrison Avenue, 8th Floor, Boston, United States
TravisBking87
TravisBking87 Apr. 3 at 4:06 PM
$PEPG Thank you Jack I made almost 9 K here because of you!
1 · Reply
asedu1968
asedu1968 Apr. 2 at 5:29 PM
$PEPG pun tang na man no !!!! up down up down
0 · Reply
asedu1968
asedu1968 Apr. 2 at 4:44 PM
$PEPG let's effing go
0 · Reply
assetmogul2
assetmogul2 Apr. 2 at 3:42 PM
$PEPG holy up and down action. What a ride
0 · Reply
LordWorld
LordWorld Apr. 2 at 1:35 PM
$PEPG
0 · Reply
LordWorld
LordWorld Apr. 1 at 9:40 PM
$PEPG
0 · Reply
asedu1968
asedu1968 Apr. 1 at 9:26 PM
$PEPG i need my money back !!! let's effing move now to 7.58 dollars
0 · Reply
LordWorld
LordWorld Apr. 1 at 8:27 PM
$PEPG Strong Buy 🚀
0 · Reply
asedu1968
asedu1968 Apr. 1 at 8:23 PM
$PEPG effing i was creamed again
0 · Reply
JDGOLD
JDGOLD Apr. 1 at 8:11 PM
$PEPG Just perking up on a bull flag Way over sold Let her run 🎰 💥🙈
0 · Reply
Latest News on PEPG
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 31, 2026, 10:33 AM EDT - 5 days ago

PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data Transcript

Mar 31, 2026, 2:12 AM EDT - 5 days ago

PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data Transcript

PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

Mar 30, 2026, 4:05 PM EDT - 5 days ago

PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

US FDA puts partial clinical hold on PepGen's muscle disease drug trial

Mar 4, 2026, 4:56 PM EST - 4 weeks ago

US FDA puts partial clinical hold on PepGen's muscle disease drug trial

PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights

Mar 4, 2026, 4:05 PM EST - 4 weeks ago

PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights

PepGen Announces Regulatory Updates on FREEDOM2

Mar 4, 2026, 4:03 PM EST - 4 weeks ago

PepGen Announces Regulatory Updates on FREEDOM2

PepGen to Participate in the Leerink Global Healthcare Conference

Mar 3, 2026, 7:00 AM EST - 4 weeks ago

PepGen to Participate in the Leerink Global Healthcare Conference

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

Dec 9, 2025, 7:00 AM EST - 4 months ago

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

Dec 8, 2025, 7:00 AM EST - 4 months ago

PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

Nov 12, 2025, 7:05 AM EST - 5 months ago

PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 12, 2025, 7:00 AM EST - 5 months ago

PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 5 months ago

PepGen to Participate in Upcoming Investor Conferences

PepGen: DMD Discontinued, Ways To Go With DM1

Oct 7, 2025, 6:38 PM EDT - 6 months ago

PepGen: DMD Discontinued, Ways To Go With DM1

PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society

Oct 2, 2025, 7:00 AM EDT - 6 months ago

PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society

PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Sep 26, 2025, 4:01 PM EDT - 6 months ago

PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles

Sep 25, 2025, 9:46 AM EDT - 6 months ago

PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles

PepGen Announces Pricing of $100 Million Public Offering

Sep 24, 2025, 10:51 PM EDT - 6 months ago

PepGen Announces Pricing of $100 Million Public Offering

PepGen Announces Proposed Public Offering

Sep 24, 2025, 4:21 PM EDT - 6 months ago

PepGen Announces Proposed Public Offering

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

Sep 24, 2025, 4:16 PM EDT - 6 months ago

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 7, 2025, 8:00 AM EDT - 8 months ago

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

Jul 30, 2025, 5:41 PM EDT - 8 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

Jul 29, 2025, 10:33 AM EDT - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

Jul 23, 2025, 11:22 AM EDT - 9 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG

Jun 23, 2025, 9:00 AM EDT - 10 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG

Shareholders who lost money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein

Jun 16, 2025, 10:39 AM EDT - 10 months ago

Shareholders who lost money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein

PEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jun 10, 2025, 10:44 AM EDT - 10 months ago

PEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

May 29, 2025, 9:19 AM EDT - 11 months ago

PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

PepGen to discontinue development of experimental Duchenne therapy; shares drop

May 28, 2025, 6:21 PM EDT - 11 months ago

PepGen to discontinue development of experimental Duchenne therapy; shares drop

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

May 28, 2025, 4:05 PM EDT - 11 months ago

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

May 20, 2025, 7:00 AM EDT - 11 months ago

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 8, 2025, 8:00 AM EDT - 11 months ago

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

TravisBking87
TravisBking87 Apr. 3 at 4:06 PM
$PEPG Thank you Jack I made almost 9 K here because of you!
1 · Reply
asedu1968
asedu1968 Apr. 2 at 5:29 PM
$PEPG pun tang na man no !!!! up down up down
0 · Reply
asedu1968
asedu1968 Apr. 2 at 4:44 PM
$PEPG let's effing go
0 · Reply
assetmogul2
assetmogul2 Apr. 2 at 3:42 PM
$PEPG holy up and down action. What a ride
0 · Reply
LordWorld
LordWorld Apr. 2 at 1:35 PM
$PEPG
0 · Reply
LordWorld
LordWorld Apr. 1 at 9:40 PM
$PEPG
0 · Reply
asedu1968
asedu1968 Apr. 1 at 9:26 PM
$PEPG i need my money back !!! let's effing move now to 7.58 dollars
0 · Reply
LordWorld
LordWorld Apr. 1 at 8:27 PM
$PEPG Strong Buy 🚀
0 · Reply
asedu1968
asedu1968 Apr. 1 at 8:23 PM
$PEPG effing i was creamed again
0 · Reply
JDGOLD
JDGOLD Apr. 1 at 8:11 PM
$PEPG Just perking up on a bull flag Way over sold Let her run 🎰 💥🙈
0 · Reply
jackrabbit1
jackrabbit1 Apr. 1 at 7:58 PM
$PEPG comon bitch let's make your move up
0 · Reply
LordWorld
LordWorld Apr. 1 at 6:36 PM
$PEPG 5 $
0 · Reply
asedu1968
asedu1968 Apr. 1 at 4:50 PM
$PEPG is this dead shit , it's not moving at all
2 · Reply
jdkd4
jdkd4 Apr. 1 at 3:14 PM
$PEPG @jacksparo securing profit!! Thanks again for the alert, Jack!
1 · Reply
jackrabbit1
jackrabbit1 Apr. 1 at 2:53 PM
$PEPG looking for 2+ today
0 · Reply
jdkd4
jdkd4 Apr. 1 at 2:37 PM
$PEPG @jacksparo i’ve made three sales so far today, this one’s the biggest. I’m up 20k on this. Not bad for 24 hours of work. I must say Jack sparrow is amazing, he has made me a lot of money, so far I’m up over 35k this week! Thank you Jack!! another thing he has taught me which is so valuable, and the reason I used to lose money was that I failed to take profit for FOMO.
1 · Reply
Dragan7
Dragan7 Apr. 1 at 2:06 PM
$PEPG There are in my conservative estimates 20 M shorts, it will be mad rush to cover after 2. GLA......
0 · Reply
Silverstripe
Silverstripe Apr. 1 at 2:04 PM
$PEPG next pop will happen when "mice" issue is cleared
0 · Reply
Silverstripe
Silverstripe Apr. 1 at 2:04 PM
$PEPG the programm is underway and it's basically pure high risk/reward game. Since I deep underwater - it's nothing to lose and I'll be waiting , but recent follow up comms is encouraging. There are buyers today and it's a good sign!
0 · Reply
Adamchristlover
Adamchristlover Apr. 1 at 1:59 PM
$CYCN $RCKT $PEPG Sparo is the real deal @jacksparo a lot of money I made with him!
0 · Reply
jacksparo
jacksparo Apr. 1 at 1:57 PM
$PEPG From my suggested entry yesterday in my Live Telegram group! Almost 37% profit! Enjoy 📈📈! Every thing documented!
0 · Reply
Rockywalia
Rockywalia Apr. 1 at 1:55 PM
$PEPG this looks quite convincing to me, but stock will be in the dog house in this market because of the outlier.
0 · Reply